Abstract PO-165: Prevalence of metabolic syndrome among cancer survivors: An NHANES study

Abstract

Abstract INTRODUCTION The purpose of this study was to determine the prevalence of metabolic syndrome (MetS) and its components by race and ethnicity in cancer survivors (CS) compared to participants without a self-reported history of cancer with (CD) and without (NCD) a chronic disease diagnosis. METHODS Using National Health and Nutrition Examination Survey (NHANES) data from 2015 to 2018, the prevalence of metabolic syndrome (MetS) was evaluated among respondents 50 years and older. MetS criteria was based on the 2005 National Cholesterol Education Program's Adult Treatment Panel III. MetS is diagnosed when three of the following five factors are present: low HDL, elevated triglycerides, elevated blood pressure, impaired fasting glucose, and elevated waist circumference. Weighted data were used to estimate the prevalence of metabolic syndrome, stratified by gender, sex, and race/ethnicity. Chi-square test was used to assess group comparisons respectively. RESULTS Approximately, two thirds of all respondents met the criteria for MetS, of which 37% were Non-Hispanic White (NHW), 30.2% were Non-Hispanic Blacks (NHB), and 25.7% were Hispanic or Mexican Americans (Hisp) (p<0.001). Of the five factors in the MetS criteria, elevated TG (p=0.012), elevated glucose (p=0.009), and elevated blood pressure (p<0.001) were significantly associated with NHW, NHB, and Hisp participants who met the MetS criteria. Among those with MetS, 61.5% of NHW, 68.0% of NHB, and 65.6% of Hisp participants had at least one chronic disease (CD), whereas 22.1% of NHW, 10.9% of NHB, and 9.3% of Hisp were cancer survivors (CS) (p<0.001). Of the CS with MetS, the highest reported cancer was non-melanoma skin cancer (35.2%) in NHW, prostate cancer (39.5%) in NHB, and breast cancer (28.5%) in Hisp (p<0.001). CONCLUSION Due to increasing numbers of CS, comorbidities such as MetS have become a concern for healthcare providers. A better understanding of the association between MetS, its factors, and specific cancer sites can provide insight into providing complete clinical care to CS, especially if there are differences by race or ethnicity. Citation Format: Adaora Ezeani, Tanya Agurs-Collins. Prevalence of metabolic syndrome among cancer survivors: An NHANES study [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr PO-165.